1. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience
- Author
-
Ritesh Kumar, Suresh C. Sharma, Anjan Bera, Rupali Aggarwal, Kanchan K Mukherjee, Divya Khosla, Shabab Lalit Angurana, Pankaj Kumar, and Narendra Kumar
- Subjects
Oncology ,medicine.medical_specialty ,Multivariate analysis ,medicine.medical_treatment ,temozolomide ,Glioblastoma multiforme ,survival ,lcsh:RC321-571 ,Text mining ,Internal medicine ,medicine ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,radiotherapy ,Chemotherapy ,Temozolomide ,business.industry ,Proportional hazards model ,General Neuroscience ,prognostic factors ,Lomustine ,Surgery ,Log-rank test ,Radiation therapy ,Original Article ,Neurology (clinical) ,business ,medicine.drug - Abstract
Aims: We present retrospective analysis of patients of glioblastoma multiforme (GBM) and discuss clinical characteristics, various treatment protocols, survival outcomes, and prognostic factors influencing survival. Materials and Methods: From January 2002 to June 2009, 439 patients of GBM were registered in our department. The median age of patients was 50 years, 66.1% were males, and 75% underwent complete or near-total excision. We evaluated those 360 patients who received radiotherapy (RT). Radiotherapy schedule was selected depending upon pre-RT Karnofsky Performance Status (KPS). Patients with KPS < 70 (Group I, n = 48) were planned for RT dose of 30-35 Gy in 10-15 fractions, and patients with KPS ≥ 70 (Group II, n = 312) were planned for 60 Gy in 30 fractions. In group I, six patients and in group II, 89 patients received some form of chemotherapy (lomustine or temozolomide). Statistical Analysis Used: Statistical analysis was done using Statistical Package for Social Sciences, version 12.0. Overall survival (OS) was calculated using Kaplan-Meier method, and prognostic factors were determined by log rank test. The Cox proportional hazards model was used for multivariate analysis. Results: The median follow-up was 7.53 months. The median and 2-year survival rates were 6.33 months and 2.24% for group I and 7.97 months and 8.21% for group II patients, respectively ( P = 0.001). In multivariate analysis, site of tumor (central vs. others; P = 0.006), location of tumor (parietal lobe vs. others; P = 0.003), RT dose (
- Published
- 2013